SOUTH SAN FRANCISCO, Calif., Mar. 06, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company delivering therapies for inner ear disorders, today announced a presentation at the upcoming 15th Asia Oceania ORL-HNS Congress, to be held March 8-12, 2023 in Brisbane, Australia.
Dr. Jafri Kuthubutheen will join the session “Vestibular: Surgical vertigo” for an oral presentation related to Spiral’s SPT-2101 program for Meniere’s disease with title “A Novel Sustained Release Dexamethasone Gel Formulation Administered to the Round Window Under Endoscopic Visualization in Patients with Meniere’s Disease”
Date: Friday, March 10, 2023
Time: 3:30 PM – 5:00 PM
Dr. Jafri Kuthubutheen, the Principal Investigator for the SPT-2101 trial on Meniere’s disease, is a distinguished otolaryngologist with an extensive background in the field of ear disorders. After graduating from the University of Western Australia with a Bachelor of Medicine and a Bachelor of Surgery with Honours in 2002, he pursued specialist ENT training and obtained his Fellowship in Otolaryngology Head and Neck Surgery in 2010. Dr. Kuthubutheen earned his PhD in the field of Cochlear Implantation from the University of Western Australia in 2017. With a strong commitment to education and research, Dr. Kuthubutheen has presented at numerous conferences and serves as the ENT Clinical Lead in the Kimberley Region of Western Australia and Medical Advisor to the Ear Science Institute of Australia.
About Spiral Therapeutics
Spiral Therapeutics is a clinical-stage company delivering therapies for inner ear disorders. Spiral’s novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea. Spiral is advancing a therapeutic pipeline with focus on balance disorders and hearing loss. Spiral’s lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of Meniere’s disease. For more information, visit: www.spiraltx.com